Today’s Market Runner: Is Selling ANI Pharmaceuticals Inc Here a Winning Strategy?

Today's Market Runner: Is Selling ANI Pharmaceuticals Inc Here a Winning Strategy?

The stock of ANI Pharmaceuticals Inc (NASDAQ:ANIP) is a huge mover today! The stock decreased 3.82% or $2.02 on November 8, hitting $50.82. About 165,717 shares traded hands. ANI Pharmaceuticals Inc (NASDAQ:ANIP) has risen 28.97% since April 6, 2016 and is uptrending. It has outperformed by 27.02% the S&P500.
The move comes after 7 months negative chart setup for the $618.81 million company. It was reported on Nov, 8 by Barchart.com. We have $47.77 PT which if reached, will make NASDAQ:ANIP worth $37.13M less.

ANI Pharmaceuticals Inc (NASDAQ:ANIP) Ratings Coverage

Out of 5 analysts covering ANI Pharma (NASDAQ:ANIP), 4 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 80% are positive. ANI Pharma has been the topic of 13 analyst reports since July 31, 2015 according to StockzIntelligence Inc. Roth Capital upgraded ANI Pharmaceuticals Inc (NASDAQ:ANIP) rating on Monday, September 28. Roth Capital has “Buy” rating and $60 price target. The stock of ANI Pharmaceuticals Inc (NASDAQ:ANIP) earned “Outperform” rating by Oppenheimer on Friday, July 31. As per Tuesday, July 19, the company rating was upgraded by Oppenheimer. The company was initiated on Friday, November 13 by Standpoint Research. The firm earned “Outperform” rating on Friday, August 5 by Oppenheimer. TH Capital upgraded ANI Pharmaceuticals Inc (NASDAQ:ANIP) rating on Monday, September 28. TH Capital has “Buy” rating and $60 price target. Raymond James initiated the stock with “Strong Buy” rating in Thursday, June 23 report. The stock has “Neutral” rating given by TH Capital on Tuesday, August 4. The firm earned “Hold” rating on Tuesday, May 24 by Standpoint Research. The firm has “Buy” rating given on Wednesday, September 2 by TheStreet.

According to Zacks Investment Research, “ANI Pharmaceuticals, Inc. is a specialty pharmaceutical company. It engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The company offers liquid, powder, oral solid dose, cough/cold products, antacids, laxatives, stomach remedies as well as hydrocortisone retention enema, esterified estrogen and methyltestosterone, fluvoxamine maleate tablets, hydrocortisone rectal suspension, metoclopramide oral solution, opium tincture and metoclopramide tablets. In addition, it offers contract manufacturing services for other pharmaceutical companies. The company serves through wholesalers, smaller regional distributors and chains and pharmacy and retail outlets primarily in the United States. ANI Pharmaceuticals, Inc., formerly known as BioSante Pharmaceuticals, Inc., is headquartered in Baudette, MN.”

Insitutional Activity: The institutional sentiment increased to 1.51 in Q2 2016. Its up 0.46, from 1.05 in 2016Q1. The ratio improved, as 14 funds sold all ANI Pharmaceuticals Inc shares owned while 31 reduced positions. 28 funds bought stakes while 40 increased positions. They now own 5.41 million shares or 2.90% less from 5.57 million shares in 2016Q1.
Goldman Sachs reported 9,588 shares or 0% of all its holdings. Suntrust Banks owns 5,091 shares or 0% of their US portfolio. Prudential Fin, a New Jersey-based fund reported 18,700 shares. Fincl Architects holds 0% or 275 shares in its portfolio. Gemmer Asset Mgmt Limited Liability Corporation has invested 0% of its portfolio in ANI Pharmaceuticals Inc (NASDAQ:ANIP). Menta Cap Ltd Liability has 16,750 shares for 0.13% of their US portfolio. Fny Managed Accounts Ltd Co holds 0% of its portfolio in ANI Pharmaceuticals Inc (NASDAQ:ANIP) for 1,506 shares. Creative Planning has 0% invested in the company for 451 shares. Mutual Of America Cap Mgmt Ltd owns 29,978 shares or 0.04% of their US portfolio. Geode Cap holds 0% or 54,845 shares in its portfolio. Texas Permanent School Fund owns 5,800 shares or 0% of their US portfolio. New York State Common Retirement Fund holds 7,900 shares or 0% of its portfolio. Moreover, Pinebridge Invs Ltd Partnership has 0% invested in ANI Pharmaceuticals Inc (NASDAQ:ANIP) for 924 shares. Ardsley Advisory Prtn, a Connecticut-based fund reported 45,000 shares. Loomis Sayles And Lp has 0% invested in the company for 103 shares.

Insider Transactions: Since August 8, 2016, the stock had 0 buys, and 2 selling transactions for $3.35 million net activity. Shares for $838,209 were sold by Schrepfer Robert W on Monday, August 8. PRZYBYL ARTHUR had sold 37,455 shares worth $2.51 million.

More notable recent ANI Pharmaceuticals Inc (NASDAQ:ANIP) news were published by: Prnewswire.com which released: “ANI Pharmaceuticals Schedules Conference Call to Discuss Third Quarter and …” on October 27, 2016, also Prnewswire.com with their article: “ANI Pharmaceuticals Announces FDA Approval and Immediate Launch of Nilutamide …” published on July 18, 2016, Prnewswire.com published: “ANI Pharmaceuticals Announces Launch of Hydroxyprogesterone Caproate Injection …” on June 28, 2016. More interesting news about ANI Pharmaceuticals Inc (NASDAQ:ANIP) were released by: Prnewswire.com and their article: “ANI Pharmaceuticals Reports Record Second Quarter Results and Increases Full …” published on August 04, 2016 as well as Prnewswire.com‘s news article titled: “ANI Pharmaceuticals Schedules Conference Call to Discuss Second Quarter and …” with publication date: July 28, 2016.

ANIP Company Profile

ANI Pharmaceuticals, Inc. (ANI), incorporated on April 11, 2001, is an integrated specialty pharmaceutical company. The Firm is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company’s focused areas of product development include anti-cancer (oncolytics), hormones and steroids, and complex formulations. The Firm has approximately two pharmaceutical manufacturing facilities located in Baudette, Minnesota that are capable of producing oral solid dose products, as well as liquids and topicals, controlled substances, and potent products. The Company’s two facilities have a combined manufacturing, packaging and laboratory capacity totaling approximately 173,000 square feet. The facilities are specialized with various capabilities, enabling the Company to manufacture liquid, powder, and oral solid-dose products, topicals, controlled substances and products. It also performs contract manufacturing for other pharmaceutical companies.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment